Senda Biosciences, Inc. is pioneering a new field of medicine called Intersystems Biology. People are a system of systems—bot ... h human and non-human. The constant molecular exchange between the hundreds of trillions of human and non-human cells within us, such as plant and bacterial cells, defines life as profoundly as our genetics. Senda is systematically harnessing these powerful molecular exchanges—the product of millennia of co-evolution—to create new classes of programmable medicines. Built on insights from Intersystems Biology, Senda’s X-VIA™ drug development platform is the first-ever atlas of interspecies exchange mechanisms, enabling next-generation nucleic acid, genetic and protein-based therapies. These therapies will enable new frontiers for medicines, such as programmable tissue targeting beyond the liver for nucleic acid, cell, and gene therapies; tunable immunomodulation for both in vivo immune system stimulation and suppression; repeatable dosing of therapeutic modalities that were previously impossible; and multiple routes of administration, including enabling oral routes for large biomolecules for the first time. Senda was unveiled by Flagship Pioneering in October 2020, and the company entered into a strategic collaboration with Nestlé Health Science in 2021 focused on novel nutritional therapies for a wide range of metabolic conditions. Senda is based in Cambridge, MA. read more